322 related articles for article (PubMed ID: 22654722)
1. Impact and Therapeutic Potential of PPARs in Alzheimer's Disease.
Heneka MT; Reyes-Irisarri E; Hüll M; Kummer MP
Curr Neuropharmacol; 2011 Dec; 9(4):643-50. PubMed ID: 22654722
[TBL] [Abstract][Full Text] [Related]
2. PPARs in Alzheimer's Disease.
Kummer MP; Heneka MT
PPAR Res; 2008; 2008():403896. PubMed ID: 18645613
[TBL] [Abstract][Full Text] [Related]
3. PPARs in the brain.
Heneka MT; Landreth GE
Biochim Biophys Acta; 2007 Aug; 1771(8):1031-45. PubMed ID: 17569578
[TBL] [Abstract][Full Text] [Related]
4. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.
Heneka MT; Landreth GE; Hüll M
Nat Clin Pract Neurol; 2007 Sep; 3(9):496-504. PubMed ID: 17805244
[TBL] [Abstract][Full Text] [Related]
5. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update.
Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M
Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284
[TBL] [Abstract][Full Text] [Related]
6. PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease.
Kumar M; Ashok SA; Datusalia AK; Khatik GL
Med Chem; 2024 May; ():. PubMed ID: 38726789
[TBL] [Abstract][Full Text] [Related]
7. Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate.
Pizcueta P; Vergara C; Emanuele M; Vilalta A; Rodríguez-Pascau L; Martinell M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834611
[TBL] [Abstract][Full Text] [Related]
8. Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets.
Cardoso S; Santos R; Correia S; Carvalho C; Zhu X; Lee HG; Casadesus G; Smith MA; Perry G; Moreira PI
Pharmaceuticals (Basel); 2009 Dec; 2(3):250-286. PubMed ID: 27713238
[TBL] [Abstract][Full Text] [Related]
9. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
Landreth G; Jiang Q; Mandrekar S; Heneka M
Neurotherapeutics; 2008 Jul; 5(3):481-9. PubMed ID: 18625459
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders.
Agarwal S; Yadav A; Chaturvedi RK
Biochem Biophys Res Commun; 2017 Feb; 483(4):1166-1177. PubMed ID: 27514452
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma.
Vallée A; Lecarpentier Y
Front Neurosci; 2016; 10():459. PubMed ID: 27807401
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.
Yan Q; Zhang J; Liu H; Babu-Khan S; Vassar R; Biere AL; Citron M; Landreth G
J Neurosci; 2003 Aug; 23(20):7504-9. PubMed ID: 12930788
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease.
Feinstein DL
Diabetes Technol Ther; 2003; 5(1):67-73. PubMed ID: 12725709
[TBL] [Abstract][Full Text] [Related]
14. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
Heneka MT; Sastre M; Dumitrescu-Ozimek L; Hanke A; Dewachter I; Kuiperi C; O'Banion K; Klockgether T; Van Leuven F; Landreth GE
Brain; 2005 Jun; 128(Pt 6):1442-53. PubMed ID: 15817521
[TBL] [Abstract][Full Text] [Related]
15. Targeting PPARalpha in Alzheimer's Disease.
D'Orio B; Fracassi A; Ceru MP; Moreno S
Curr Alzheimer Res; 2018 Feb; 15(4):345-354. PubMed ID: 28474570
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
Sertznig P; Seifert M; Tilgen W; Reichrath J
Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
[TBL] [Abstract][Full Text] [Related]
17. The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease.
Nicolakakis N; Hamel E
Front Aging Neurosci; 2010; 2():. PubMed ID: 20725514
[TBL] [Abstract][Full Text] [Related]
18. PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.
Zolezzi JM; Santos MJ; Bastías-Candia S; Pinto C; Godoy JA; Inestrosa NC
Biol Rev Camb Philos Soc; 2017 Nov; 92(4):2046-2069. PubMed ID: 28220655
[TBL] [Abstract][Full Text] [Related]
19. PPARgamma, neuroinflammation, and disease.
Mrak RE; Landreth GE
J Neuroinflammation; 2004 May; 1(1):5. PubMed ID: 15285797
[TBL] [Abstract][Full Text] [Related]
20. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
Skerrett R; Pellegrino MP; Casali BT; Taraboanta L; Landreth GE
J Biol Chem; 2015 Aug; 290(35):21591-602. PubMed ID: 26163517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
